ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 10 months ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs pour obefazimod 25 mg chez les patients atteints de RCH modérée à sévère après 2 ans de maintenance. Analyse intermédiaire d'une étude de 6 ans

Abivax Obefazimod Efficacité RCH Rémission Clinique
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 10 months ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency

Abivax Obefazimod Ulcerative Colitis Safety Efficacy
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 10 months ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs d'une analyse intermédiaire sur l'efficacité d'obefazimod 25 mg pour les patients atteints de RCH modérée à sévère après 2 ans de traitement

Abivax Obefazimod Efficacité Tolérance RCH Modérée
BRIEF

published on 09/26/2024 at 08:35, 1 year 10 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Obefazimod Ulcerative Colitis Phase 2b Study UEG Week 2024
BRIEF

published on 09/26/2024 at 08:35, 1 year 10 months ago

Abivax présentera trois résumés sur l'obéfazimod dans la rectocolite hémorragique lors de la semaine UEG 2024

Abivax Obefazimod Rectocolite Hémorragique Étude De Phase 2b Semaine UEG 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 10 months ago

Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024. Les présentations mettent en lumière l'efficacité et la sécurité du traitement

Abivax Obefazimod Phase 2b Rectocolite Hémorragique UEG Week
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 10 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 10 months ago

Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024

Abivax Obefazimod Rectocolite Hémorragique Traitement UEG Week 2024
BRIEF

published on 09/25/2024 at 22:06, 1 year 10 months ago

Abivax Announces Ulcerative Colitis Combination Therapy Strategy and Preclinical Data

Obefazimod Ulcerative Colitis Preclinical Data Combination Therapy Etrasimod
BRIEF

published on 09/25/2024 at 22:06, 1 year 10 months ago

Abivax annonce sa stratégie de traitement combiné contre la rectocolite hémorragique et ses données précliniques

Obefazimod Rectocolite Hémorragique Données Précliniques Etrasimod Thérapie Combinée

Published on 08/07/2026 at 00:45, 5 hours 7 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 6 hours 37 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 7 hours 37 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 7 hours 47 minutes ago

Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 7 hours 52 minutes ago

Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE

View all ACCESSWIRE

Published on 08/06/2026 at 22:50, 7 hours 2 minutes ago

Amrize Reports Second Quarter 2026 Results
Published on 08/06/2026 at 22:15, 7 hours 37 minutes ago

BIRKENSTOCK SEEKS TO FILL VACANCY IN THE BOARD OF DIRECTORS WITH AN INDEPENDENT DIRECTOR, FOLLOWING ALEXANDRE ARNAULT'S RESIGNATION DUE TO PROFESSIONAL COMMITTMENTS
Published on 08/06/2026 at 21:45, 8 hours 7 minutes ago

FP Markets Analysis: Japanese Yen at a Crossroads as Markets Weigh Next Move
Published on 08/06/2026 at 19:05, 10 hours 47 minutes ago

Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEO
Published on 08/06/2026 at 18:24, 11 hours 27 minutes ago

EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026

View all EQS

Published on 08/06/2026 at 18:26, 11 hours 26 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 11 hours 26 minutes ago

Air Liquide droits de vote au 31 juillet 2026
Published on 08/06/2026 at 17:46, 12 hours 6 minutes ago

Déclaration des droits de vote à fin juillet 2026
Published on 08/06/2026 at 17:45, 12 hours 7 minutes ago

Déclaration des droits de vote à fin juillet 2026
Published on 08/06/2026 at 17:45, 12 hours 7 minutes ago

Declaration of voting rights at the end of July 2026

View all LES ECHOS COMFI WIRE

News